CAMP4 THERAPEUTICS CORP(NASDAQ:CAMP) stock News

CAMP Latest News, Press Relases and Analysis

All

Press Releases

5 days ago - By: Chartmill - Mentions: TC OXM DGLY RNA ...

Wednesday's after hours session: top gainers and losers

5 days ago - By: Benzinga - Mentions: KEQU BLRX VNRX RNA ...

12 Health Care Stocks Moving In Wednesday's After-Market Session

5 days ago - By: Benzinga - Mentions: ACTU GNPX PMVP TVTX ...

12 Health Care Stocks Moving In Wednesday's Intraday Session

6 days ago - By: CAMP4 Therapeutics

CAMP4 Announces an Oversubscribed Private Placement of up to $100 Million to Advance First-in-Class Treatment for SYNGAP1-Related Disorders

6 days ago - By: CAMP4 Therapeutics

CAMP4 Announces an Oversubscribed Private Placement of up to $100 Million to Advance First-in-Class Treatment for SYNGAP1-Related Disorders

a month ago - By: The Motley Fool

Camp4 Reports Q2 Revenue Beats Estimates

a month ago - By: CAMP4 Therapeutics

CAMP4 Reports Second Quarter 2025 Financial Results and Corporate Highlights

a month ago - By: CAMP4 Therapeutics

CAMP4 Reports Second Quarter 2025 Financial Results and Corporate Highlights

4 months ago - By: CAMP4 Therapeutics

CAMP4 Presents Translational Data from SYNGAP1-Related Disorders Program Showcasing Increased Protein in Non-Human Primates and Reviews Preclinical and Detailed Single Ascending Dose Safety Data from Urea Cycle Disorders Program at the 28th American

4 months ago - By: CAMP4 Therapeutics

CAMP4 Presents Translational Data from SYNGAP1-Related Disorders Program Showcasing Increased Protein in Non-Human Primates and Reviews Preclinical and Detailed Single Ascending Dose Safety Data from Urea Cycle Disorders Program at the 28th American

4 months ago - By: CAMP4 Therapeutics

CAMP4 Reports First Quarter 2025 Financial Results and Corporate Highlights

4 months ago - By: CAMP4 Therapeutics

CAMP4 Reports First Quarter 2025 Financial Results and Corporate Highlights

5 months ago - By: CAMP4 Therapeutics

CAMP4 to Present New Preclinical Data from its Urea Cycle Disorders and SYNGAP1-Related Disorders Programs at the 28th American Society of Gene and Cell Therapy Annual Meeting

5 months ago - By: CAMP4 Therapeutics

CAMP4 to Present New Preclinical Data from its Urea Cycle Disorders and SYNGAP1-Related Disorders Programs at the 28th American Society of Gene and Cell Therapy Annual Meeting

6 months ago - By: CAMP4 Therapeutics

CAMP4 Reports Full Year 2024 Financial Results and Provides Corporate Update

6 months ago - By: CAMP4 Therapeutics

CAMP4 Reports Full Year 2024 Financial Results and Provides Corporate Update

6 months ago - By: CAMP4 Therapeutics

CAMP4 Appoints Multiple Industry Veterans to its Board of Directors

6 months ago - By: CAMP4 Therapeutics

CAMP4 Appoints Multiple Industry Veterans to its Board of Directors

7 months ago - By: CAMP4 Therapeutics

CAMP4 to Participate in Upcoming Investor Conferences

7 months ago - By: CAMP4 Therapeutics

CAMP4 to Participate in Upcoming Investor Conferences

8 months ago - By: CAMP4 Therapeutics

CAMP4 to Present at the 43rd Annual J.P. Morgan Healthcare Conference

8 months ago - By: CAMP4 Therapeutics

CAMP4 Provides Corporate Updates and Highlights Key Upcoming Milestones

8 months ago - By: CAMP4 Therapeutics

CAMP4 Provides Corporate Updates and Highlights Key Upcoming Milestones

9 months ago - By: CAMP4 Therapeutics - Mentions: KRRO

CAMP4 Appoints John Maraganore and Rachel Meyers as Strategic Advisors

10 months ago - By: CAMP4 Therapeutics

CAMP4 to Participate in the Piper Sandler 36th Annual Healthcare Conference

10 months ago - By: CAMP4 Therapeutics

CAMP4 to Participate in the Piper Sandler 36th Annual Healthcare Conference

10 months ago - By: CAMP4 Therapeutics

CAMP4 THERAPEUTICS CORP (CAMP) Stock News

CAMP Latest News, Press Relases and Analysis

Wednesday's after hours session: top gainers and losers

12 Health Care Stocks Moving In Wednesday's After-Market Session

12 Health Care Stocks Moving In Wednesday's Intraday Session

CAMP4 Announces an Oversubscribed Private Placement of up to $100 Million to Advance First-in-Class Treatment for SYNGAP1-Related Disorders

CAMP4 Announces an Oversubscribed Private Placement of up to $100 Million to Advance First-in-Class Treatment for SYNGAP1-Related Disorders

Camp4 Reports Q2 Revenue Beats Estimates

CAMP4 Reports Second Quarter 2025 Financial Results and Corporate Highlights

CAMP4 Reports Second Quarter 2025 Financial Results and Corporate Highlights

CAMP4 Presents Translational Data from SYNGAP1-Related Disorders Program Showcasing Increased Protein in Non-Human Primates and Reviews Preclinical and Detailed Single Ascending Dose Safety Data from Urea Cycle Disorders Program at the 28th American

CAMP4 Presents Translational Data from SYNGAP1-Related Disorders Program Showcasing Increased Protein in Non-Human Primates and Reviews Preclinical and Detailed Single Ascending Dose Safety Data from Urea Cycle Disorders Program at the 28th American

CAMP4 Reports First Quarter 2025 Financial Results and Corporate Highlights

CAMP4 Reports First Quarter 2025 Financial Results and Corporate Highlights

CAMP4 to Present New Preclinical Data from its Urea Cycle Disorders and SYNGAP1-Related Disorders Programs at the 28th American Society of Gene and Cell Therapy Annual Meeting

CAMP4 to Present New Preclinical Data from its Urea Cycle Disorders and SYNGAP1-Related Disorders Programs at the 28th American Society of Gene and Cell Therapy Annual Meeting

CAMP4 Reports Full Year 2024 Financial Results and Provides Corporate Update

CAMP4 Reports Full Year 2024 Financial Results and Provides Corporate Update

CAMP4 Appoints Multiple Industry Veterans to its Board of Directors

CAMP4 Appoints Multiple Industry Veterans to its Board of Directors

CAMP4 to Participate in Upcoming Investor Conferences

CAMP4 to Participate in Upcoming Investor Conferences

CAMP4 to Present at the 43rd Annual J.P. Morgan Healthcare Conference

CAMP4 Provides Corporate Updates and Highlights Key Upcoming Milestones

CAMP4 Provides Corporate Updates and Highlights Key Upcoming Milestones

CAMP4 Appoints John Maraganore and Rachel Meyers as Strategic Advisors

CAMP4 to Participate in the Piper Sandler 36th Annual Healthcare Conference

CAMP4 to Participate in the Piper Sandler 36th Annual Healthcare Conference

CAMP4 Reports Third Quarter 2024 Financial Results